MAP2K7 and neoplasm: Moreover, WES data on the biopsies from a melanoma patient showed that the oncogenic mutation PI3KCAE545K pre-existed in a rare tumor cell subpopulation prior to combination therapy of the CDK4/6 inhibitor ribociclib and the MEK inhibitor MEK162.